Sight Sciences appoints medtech veteran Gary Burbach to board of directors

Sight Sciences, Inc.

Appointed as Class II director effective April 21, 2025; term expires at 2026 annual meeting.
Former CEO of Thoratec (acquired by St. Jude/Abbott); also serves on BWX Technologies and Procyrion boards.
CEO Paul Badawi highlighted Burbach's commercial and operational expertise in medtech.
Eligible for non-employee director compensation; no committee assignments yet determined.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gerhard F. Burbach

Director

SGHT · Sight Sciences, Inc.

Effective: 2025-04-21
Filed: April 22, 2025, 7:59 PM ET

On April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gerhard F. Burbach was appointed as Director at Sight Sciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.

View on SEC.gov

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-056724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.